Home Cell Cycle MPS1

MPS1

Other Cell Cycle Related Inhibitors

CDK ROCK Wee1 Aurora Kinase Chk PLK APC Rho Myc DYRK
Cat.No. Product Name Information Product Use Citations Product Validations
S2731 AZ 3146 AZ3146 is a selective Mps1 inhibitor with IC50 of ~35 nM, contributes to recruitment of CENP-E (kinesin-related motor protein), less potent to FAK, JNK1, JNK2, and Kit.
Cell Rep Med, 2025, 6(6):102160
EMBO J, 2025, 44(13):3794-3823
J Cell Biol, 2025, 224(6)e202409219
Verified customer review of AZ 3146
S7488 MPI-0479605 MPI-0479605 is an ATP competitive and selective inhibitor of mitotic kinase Mps1 with IC50 of 1.8 nM, >40-fold selectivity over other kinases.
Adv Sci (Weinh), 2025, 12(45):e07839
Sci Rep, 2024, 14(1):15912
Mol Biol Cell, 2024, 35(8):br15
S8215 BAY 1217389 BAY 1217389 is an orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1) with IC50 values below 10 nmol/L while showing an excellent selectivity profile.
Sci Rep, 2024, 14(1):15912
Nat Commun, 2023, 10.1038/s41467-023-43274-3
Dev Cell, 2023, 58(3):192-210.e11
S8214 Empesertib (BAY1161909) Empesertib (BAY1161909, Mps1-IN-5), a derivative of triazolopyridine, is an orally bioavailable, selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase with IC50 of <1 nM. This compound has potential antineoplastic activity.
Commun Biol, 2025, 8(1):1011
Sci Adv, 2023, 9(3):eadd6982
S8911 BOS172722 BOS172722 is a monopolar spindle 1 (MPS1) checkpoint inhibitor with IC50 of 11 nM, Ki of 0.11 nM.
Cancer Res, 2025, 85(15):2921-2938
Cancer Res, 2025, 10.1158/0008-5472.CAN-25-0999
E1428 Mps1-IN-6 (Compound 9) Mps1-IN-6 (Compound 9) is a potent Mps1 inhibitor with IC50 of 6.4 nM. It also exhibits antiproliferative and anti-tumor activity in breast cancer cells.
S6768 CC-671 CC-671 is a selectively dual inhibitor of TTK (human protein kinase monopolar spindle 1 [hMps1]) and CDC like kinase 2 (CLK2) with IC50s of 5 nM and 3 nM for TTK and CLK2, respectively.